ClinicalTrials.gg
RecruitingNCT07239856DIGIGOATUpdated Nov 20, 2025

Goat vs. Cow Milk Digestive Tolerance

An interventional study of Cow milk and Goat Milk in Milk Intolerance, Milk Hypersensitivity and Cow Milk Protein Sensitivity, sponsored by Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to assess to what extent goat's milk is better tolerated than cow's milk among individuals who report being intolerant to cow's milk, and, if so, to understand the underlying factors. To achieve this, digestive discomfort sensations and postprandial kinetics of nutrients after ingestion of cow's or goat's milk will be compared in two populations: individuals intolerant to cow's milk but not to goat's milk, and individuals who show no symptoms of intolerance to either cow's or goat's milk. For this purpose, approaches based on stable isotope labeling of milk will be employed.

Read the detailed description

Objective:

Although milk has many nutritional benefits, such as being rich in high-quality proteins and calcium, some people limit or exclude its consumption due to poor digestive tolerance. Lactose intolerance is a well-known cause, but other factors may occur, remaining poorly understood. Goat milk is perceived by consumers as causing fewer intestinal issues than cow milk, particularly for sensitive individuals. However, there is little scientific evidence to support this perception and to confirm the supposed health benefits of goat's milk over cow's milk. The objective of this study is to assess to what extent goat's milk is better tolerated than cow's milk among individuals who report being intolerant to cow's milk, and, if so, to understand the underlying factors.

Design:

This study is crossover study, randomized for the order of testing (goat milk or cow milk), conducted in a single-blind design (participants are not informed about the test meal, which is masked by aroma), involving two groups of at least ten volunteers: individuals intolerant to cow's milk but not to goat's milk, and individuals who show no symptoms of intolerance to either cow's or goat's milk. Each subject will have consumed both milks at the end of the two sessions, with a minimum one-month interval.

Postprandial Test Procedure:

Two days before the test, subjects must exclude consumption of the main dairy products (yogurt, cheese, milk, and custard creams). Volunteers arrive in a fasted state on the investigation day and are hospitalized for one day per session. On the first visit, volunteers bring a stool sample. Upon arrival, body composition is measured via bioelectrical impedance and a venous catheter is inserted. Blood samples are taken 30 minutes pre-meal, every 30 minutes for the first 4 hours, and hourly thereafter, totaling 291 mL. Urine is collected before the meal and every 2 hours post-meal. Respiratory is measured hourly using an indirect calorimeter. Digestive tolerance and hunger are assessed hourly using questionnaires. Volunteers remain semi-reclined for about 9 hours and fast until the experiment ends, receiving hourly water.

The test meal consists of aromatized 500 ml of cow's or goat's milk, labeled with stable isotopes: nitrogen-15 and deuterium. The incorporation rate is minimal and safe for human health, commonly used in clinical studies. The 15N enrichment is measured in collected biological samples (blood, urine) to track the digestive and metabolic fate of dietary amino acids, enabling precise evaluation of nutrient availability kinetics in the body. After the investigation day, volunteers can go home post-meal. A follow-up call the next day checks for digestive symptoms, with the doctor assessing the need for symptomatic treatment.

The protocol has been approved by the Ethical Committee and authorized by the French Agency of Drugs and Health. The personal data management will be in accordance with the regulation on personal data protection ("regulation n° 2018-493 du 20 juin 2018").

02

Conditions studied

  • Milk Intolerance
  • Milk Hypersensitivity
  • Cow Milk Protein Sensitivity

Keywords

  • Digestive confort
  • Goat milk
  • Cow milk
  • Stable isotopes
  • Milk hypersensitivity
  • Milk intolerance
  • Digestion
03

In context

Lactose Intolerance

53 studies on the registry are indexed under Lactose Intolerance; 6 are open to participants now.

This study's planned enrollment of 20 is below the median of 41 across 41 interventional studies indexed under Lactose Intolerance.

Browse Lactose Intolerance studies →

Lead sponsor

Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement is the lead sponsor of 50 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who report being intolerant to cow milk but not to goat milk (one group) or tolerant to both cow milk and goat milk (another group)
  • Good general health (WHO grade = 0)
  • Affiliated with a social security scheme
  • Free, informed, and express consent, in accordance with the public health code: 'No research mentioned in 2° of Article L. 1121-1 can be conducted on a person without their free, informed, and express consent.

Exclusion criteria

Exclusion Criteria:

  • Individuals under guardianship or curatorship
  • Individuals under legal protection
  • Any known food allergies
  • Anemia: levels below 13 g/dL for men and 12 g/dL for women
  • Pregnant women or those likely to be (based on a positive urine pregnancy test at the time of inclusion)
  • Excessive alcohol consumption (>2 drinks/day). Harmful alcohol consumption is assessed by the investigator at the time of inclusion.
  • Hypertension, diabetes, digestive tract diseases (except for irritable bowel syndrome, IBS), liver or kidney diseases, severe heart disease. The presence of these conditions will be assessed by the investigator based on usual clinical criteria and the volunteers' declarations during inclusion. Hypertension: Significant arterial hypertension as determined by the investigator or systolic blood pressure greater than or equal to 140 mmHg and/or diastolic blood pressure greater than or equal to 90 mmHg on the day of inclusion. Diabetes: Type 1 or Type 2 diabetes or any fasting blood glucose level > 1.25 g/l. Digestive tract disease: Gastrointestinal disorders deemed by the investigator as (bleeding, vomiting, constipation/diarrhea grade >1), any inflammatory bowel disease, acute gastroenteritis in the month preceding the intervention. Liver disease: Any significant liver disorder as determined by the investigator or any /ALT > 2.5 times the upper normal limit.
  • Elite athletes (> 8 hours per week)
  • Blood donation in the 3 months preceding the start of the study
  • Participation in a clinical study in the 3 months preceding the study
  • Lack of free, informed, and express consent
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Cow milk intolerant

    Individuals who report being intolerant to cow's milk but not to goat's milk

    Other: Cow milk · Other: Goat Milk

  • Experimental
    Control

    Individuals who report being tolerant to both cow's milk and goat's milk.

    Other: Cow milk · Other: Goat Milk

Interventions

  • OtherCow milk

    Consuption of 500 ml of aromatized cow milk, labeled with stable isotopes: nitrogen-15 and deuterium. Body composition is measured via bioelectrical impedance. A venous catheter is inserted. Blood, urine and breath samples are taken pre-meal, and regularly during 8 hours. Digestive tolerance and hunger are assessed using questionnaires.

  • OtherGoat Milk

    Consuption of 500 ml of aromatized goat milk, labeled with stable isotopes: nitrogen-15 and deuterium. Body composition is measured via bioelectrical impedance. A venous catheter is inserted. Blood, urine and breath samples are taken pre-meal, and regularly during 8 hours. Digestive tolerance and hunger are assessed using questionnaires.

06

What researchers measure

Primary outcomes

  1. Digestive discomfort score from 0 to 8 hours post-meal

    A digestive tolerance questionnaire (Casellas, 2009) and a hunger sensation questionnaire using visual analog scales are administered hourly. These are based on scales from 1 to 10 to assess feelings of : flatulence, nausea, diarrhea, bloating, and abdominal pain.

    Time frame: 0, 1, 2, 3, 4, 5, 6, 7, 8 hours post-meal

Secondary outcomes

  1. 15N enrichment of plasma and urine fractions from 0 to 8 hours post-meal

    The measurement of isotopic enrichment of nitrogenous compounds in plasma and urine, in response to the ingestion of 15N-labeled milk proteins, provides an estimate of proteins absorption kinetic.

    Time frame: 0, 1, 2, 3, 4, 5, 6, 7, 8 hours post-meal

  2. 2H enrichment of plasma fatty acids from 0 to 8 hours post-meal

    The measurement of isotopic enrichment of fatty acids in plasma, in response to the ingestion of 2H-labeled milk lipids, provides an estimate of fatty acid absorption kinetics.

    Time frame: 0, 1, 2, 3, 4, 5, 6, 7, 8 hours post-meal

  3. 2H enrichment of plasma glucose from 0 to 8 hours post-meal

    The measurement of isotopic enrichment of glucose in plasma, in response to the ingestion of 2H-labeled milk lactose, provides an estimate of lactose absorption kinetics.

    Time frame: 0, 1, 2, 3, 4, 5, 6, 7, 8 hours post-meal

  4. Blood metabolites concentrations from 0 to 8 hours post-meal

    Analysis of the amino acid, urea, glucose, triglyceride, free fatty acid, cholesterol, and insulin concentrations in blood

    Time frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8 hours post-meal

  5. Exhaled breath gas concentrations from 0 to 8 hours post-meal

    Hydrogen (H2), methane (CH4), and carbon dioxide (CO2) concentration from exhaled air

    Time frame: 0, 1, 2, 3, 4, 5, 6, 7, 8 hours post-meal

  6. Substrate oxidation rates from 0 to 8 hours post-meal

    Fat and glucose oxidation are assessed by measuring respiratory exchanges using indirect calorimetry

    Time frame: 0, 1, 2, 3, 4, 5, 6, 7, 8 hours post-meal

  7. Intestinal microbiota composition

    Volunteers must bring a stool sample in the container previously provided to them. The samples will be analyzed using the 16S rRNA method to assess gamma and beta diversity.

    Time frame: Once at the beginning of enrollement

07

Study locations

1 of 1 sites recruiting
  • Hôpital Avicenne, 125 rue de Stalingrad
    Bobigny, 93000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

Of 22 interventional studies with no phase under Lactose Intolerance, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 17 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Nov 20, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07239856
Lead sponsor
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Sep 25, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Saviard
Contact
tanguy.saviard@agroparistech.fr
+33631312326
Maurinier
Contact
suzette.maurinier@agroparistech.fr
+33148957433

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion